Account Executive, 製薬

Tulipについて 製造業は世界経済の約20%を占めながら、最もデジタル化が遅れている産業のひとつです。TulipはMITで創業した、製造現場の作業者のために設計されたAIネイティブ・ノーコードプラットフォームです。2026年1月には評価額13億ドルを達成し、前年比二桁成長を継続しています。世界経済フォーラムのGlobal InnovatorおよびGartner Leaderにも選出されています。 日本市場について 日本は世界第4位の製薬市場であり、世界でも特に高い製造基準を持つ国のひとつです。Tulipにとっても非常に重要な戦略市場と位置づけています。三菱電機からの戦略的出資を受け、DMG MORIとは長年にわたるパートナーシップを築いてきました。これらの関係は、私たちがこの市場に真剣に向き合っている証でもあります。 AstraZeneca、Eli Lilly、J&J、中外製薬といったグローバルなリーディングカンパニーがすでにTulipを導入し、電子バッチ記録・eDHR・ラインクリアランス・逸脱管理などの業務デジタル化を進めています。 今私たちが求めているのは、その土台の上に新たな成長を築いていける方です。このポジションは、日本の製薬・ライフサイエンス業界におけるセールスのPlaybookを自ら主体的に作っていただける方を募集しております。 勤務地は日本です。2026年はフルリモート勤務で、2027年にはオフィス開設を予定しています。なお、応募時点で有効な日本の就労ビザをお持ちであることが必須となります。ビザのスポンサーシップには対応しておりません。 About Tulip Manufacturing accounts for nearly 20% of the global economy yet remains one of the least digitized industries on earth. Tulip was founded at MIT to change that — an AI-native, no-code platform built for the people on the manufacturing front line. In January 2026 we reached a $1.3B valuation and continue to grow double digits year over year. We have been recognized as a World Economic Forum Global Innovator and a Gartner leader. About the opportunity in Japan Japan is the world's fourth-largest pharmaceutical market, home to some of the most demanding manufacturing standards anywhere — and one of Tulip's most strategic markets. Mitsubishi Electric has made a strategic investment in Tulip, and DMG MORI has been a longstanding partner. These relationships reflect how seriously we are committed to this market. Global pharma leaders including AstraZeneca, Eli Lilly, J&J, and Chugai are already running on Tulip to digitize operations — from electronic batch records and eDHR to line clearance and deviation management. The market is real. The customers are real. The foundation is there. What we need now is the person who will build on it. This is a founding role: the first dedicated commercial presence for Tulip in Japan's pharmaceutical and life sciences industry. We're looking for someone who is ready to own it. This role is located in Japan - We are a remote work environment for 2026 with future plans to open up an office in 2027. Candidates must possess a valid Japanese work visa at the time of application. We are unable to provide visa sponsorship for this position. About You: - You are on the front lines working with large strategic pharmaceutical, biotech, and life sciences accounts in Japan, presenting from C-suite executives to front-line manufacturing operators and QA leaders. - You have successfully navigated complex enterprise sales into life sciences companies, with deep understanding of the long deal cycles, multi-stakeholder buying committees, and validation/qualification processes that define this industry. - Acronyms like ERP, MES, GxP, eBR, eDHR, LIMS, LES, and 21 CFR Part 11 are part of your daily conversations. - You are used to building, managing, and closing opportunities within a new pipeline — including proof of concept, validation phases, and expansion deals across global pharma networks. - You are comfortable with ambiguity and eager to contribute to building scalable sales processes and a localized GTM playbook for Japan. - Experience either working at a startup or helping to develop a new business unit within a multinational company is a plus. - Genuine, humble, and intellectually curious, with a passion for learning about pharmaceutical manufacturing, regulatory frameworks, and digital transformation. - Strong customer-centric approach, focused on building long-term relationships with regulated-industry customers. - Positive, proactive, and collaborative team player. What skills do I need? - 5+ years selling complex enterprise SaaS solutions into Pharmaceutical, Biotech or broader Life Sciences accounts in Japan, at management and executive levels. - Demonstrated history of consistently exceeding 100%+ quota, managing a diverse pipeline across multiple types of life sciences customers. - Experience selling Manufacturing